Posted by Michael Wonder on 23 Apr 2019
PHARMAC rejects own experts' view on breast cancer drug
23 April 2019 - PHARMAC has refused funding for Kadcyla, an important drug that has recently had a high media and public profile.
“This is a huge blow for women with advanced HER2 positive breast cancer who took a petition to Parliament in October 2018 calling for PHARMAC to fund this medicine,” Breast Cancer Aotearoa Chair Libby Burgess says.
Kadcyla has been refused for funding despite being recommended by PHARMAC’s own clinical experts on its Cancer Treatments Committee.
